A specific survival score for patients receiving local therapy for single brain metastasis from a gynecological malignancy

Dirk Rades, Liesa Dziggel, Steven E. Schild

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Background/Aim: Personalization of the treatment of brain metastases considering patient’s overall survival (OS) prognosis is gaining importance. This study was conducted to develop an OS score particularly for patients receiving local therapies for single brain metastasis from gynecological malignancies. Patients and Methods: In 11 patients, the following factors were retrospectively analyzed for associations with OS: Age, Karnofsky performance score (KPS), tumor type, extra-cranial metastatic sites, and time from diagnosis of gynecological malignancy to treatment of brain metastasis. Factors showing at least a strong trend were used for the score. Results: A KPS of 80-90% resulted in a significantly better OS than a KPS of 50-70% (p=0.008). Absence of extra-cranial metastases showed a strong trend (p=0.052). For the score, the following points were used: KPS 50-70%=0, KPS 80-90%=1, presence of extra-cranial metastatic sites=0, absence=1. Patients’ scores were 0, 1 or 2 points. OS rates at both 6 and 12 months were 0%, 67% and 100%, respectively (p=0.020). Conclusion: This specific score can be used to estimate OS in patients receiving local therapies for single brain metastasis from gynecological malignancies and personalize their care.

Original languageEnglish (US)
Pages (from-to)825-828
Number of pages4
JournalIn Vivo
Volume32
Issue number4
DOIs
StatePublished - Jul 1 2018

Keywords

  • Gynecological malignancies
  • Local therapies
  • Personalized care
  • Single brain metastasis
  • Survival score

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'A specific survival score for patients receiving local therapy for single brain metastasis from a gynecological malignancy'. Together they form a unique fingerprint.

Cite this